research use only

Roxadustat (FG-4592) HIF Proly Hydroxylase inhibitor

Cat.No.S1007

Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. This compound also potentiates RSL3 induced ferroptosis. Phase 3.
Roxadustat (FG-4592) HIF modulator Chemical Structure

Chemical Structure

Molecular Weight: 352.34

Quality Control

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EpSC cell Cell viability assay 5 µM or 10 µM 24 h FG-4592 increased EpSC cell viability in normoxia. 29742498
Adiposederived mesenchymal stem cells (ADMSCs) Function assay 5 μM the level of HIF-1a expression was much higher in the FG-4592-treated group than in the vehicletreated group. 27021233
Hep3B Function assay 50 to 250 uM 10 hrs Inhibition of HIF-PHD2 in human Hep3B cells assessed as HIF-1alpha protein stabilization at 50 to 250 uM after 10 hrs by Western blot method 29856623
Hep3B Function assay 50 to 250 uM 10 hrs Inhibition of HIF-PHD2 in human Hep3B cells assessed as HIF-2alpha protein stabilization at 50 to 250 uM after 10 hrs by Western blot method 29856623
Hep3B Function assay 50 uM 10 hrs Inhibition of HIF-PHD2 in human Hep3B cells assessed as upregulation of EPO mRNA level at 50 uM after 10 hrs by RT-PCR method 29856623
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 352.34 Formula

C19H16N2O5

Storage (From the date of receipt)
CAS No. 808118-40-3 Download SDF Storage of Stock Solutions

Synonyms ASP1517 Smiles CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3

Solubility

In vitro
Batch:

DMSO : 70 mg/mL (198.67 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro

Roxadustat (FG-4592) is an oral inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase currently in clinical development for the treatment of anemia. It stabilizes the activities of HIF, a cytosolic transcription factor, leading to activation of the genes associated with erythropoiesis, including erythropoietin and enzymes involved in iron metabolism. [1]

In vivo

Roxadustat (FG-4592) (50 mg/kg; i.p.; daily for 7 days) protects the survival of motor neurons and improves recovery from spinal cord injury.[2]

References

Applications

Methods Biomarkers Images PMID
Western blot HIF-α CA9 / NDRG1 / GLUT1 / GLUT3 / HK2 / PHD2 / JMJD1A / JMJD2B / JMJD2C S1007-WB1 30334352

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03303066 Completed
Anemia|Myelodysplastic Syndrome
FibroGen|AstraZeneca
June 6 2018 Phase 2|Phase 3
NCT02988973 Completed
Chronic Kidney Disease
Astellas Pharma Inc|FibroGen
January 12 2017 Phase 3
NCT02964936 Completed
Chronic Kidney Disease
Astellas Pharma Inc|FibroGen
January 11 2017 Phase 3
NCT02952040 Completed
Healthy Subjects
Astellas Pharma Inc|FibroGen
November 2016 Phase 1
NCT02952092 Completed
Hemodialysis Chronic Kidney Disease Patients With Anemia
Astellas Pharma Inc|FibroGen
November 30 2016 Phase 3
NCT02805374 Completed
Healthy Subjects
Astellas Pharma Inc|FibroGen
July 2016 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you tell me what the half-life of it is, please?

Answer:
Its half-life is around 12 hours. Please see the reference below: https://www.ncbi.nlm.nih.gov/pubmed/26846333

Signaling Pathway Map